Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial

Detailed results from the TACKLE Phase III outpatient treatment trial showed AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) provided clinically and statistically significant protection against progression to severe COVID-19 or death from any cause compared to placebo, with treatment with ...

Related Keywords

Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Great Britain ,America ,American ,Nat Microbiol ,Tixagevimab Cilgavimab ,Hugh Montgomery ,Company On Twitter ,Vanderbilt University Medical Center ,Department Of Defense ,Nasdaq ,Astrazeneca ,Department Of Health ,European Union ,Nuclear Defense ,University Of Oxford ,Biomedical Advanced Research ,Human Services ,Drug Administration ,World Health Organization ,Program Executive Office For Chemical ,Development Authority ,Washington University School Of Medicine ,Regulatory Agency ,Tm Tixagevimab Co ,Investor Relations Team ,Safety Of Intramuscular Administration ,Office Of The ,Lancet Respiratory Medicine ,Lancet Respiratory ,Intensive Care Medicine ,University College London ,Executive Vice President ,Latin America ,African American ,American Indian ,Washington University School ,Assistant Secretary ,Joint Program Executive Office ,Rare Diseases ,Intramuscular Administration ,Early Outpatient Treatment ,Lancet Respir ,Structural Basis ,Therapeutic Efficacy ,Non Human Primates ,Extended Half Life ,Sci Transl ,Antimicrobial Agents ,Antimicrob Agents ,Single Dose ,Healthy Preterm ,Pediatr Infect Dis ,New England Journal ,Antibody Treatments ,Virus Escapes Neutralization ,Therapeutic Monoclonal ,Nature Medicine ,Widespread Escape ,Neutralizing Antibody ,Tixagevimab Co Packaged ,Antibody Escape ,Weekly Epidemiological Update ,